๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hirosaki
Clinical trial register · Japan

Clinical Trials in Hirosaki, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Nagoya 53 Sapporo 41 Kashiwa 39 Yokohama 33 Tลon 23
Narrow the registerReset
Recruitment status
Phase
Site location
Nagoya53 Sapporo41 Kashiwa39 Yokohama33 Tลon23
All 114 locations
Target enrolment
to

Trials with a site in Hirosaki

8 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tลon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
675
Nagoya, Toyoake, Hirosaki, Tลon, Kurume, ลŒta, Himeji, Kobe
2025-10-08
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Nagoya, Toyoake, Hirosaki, Kashiwa, Tลon, ลŒta, Kobe, Takarazuka
2024-06-10
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
868
Nagoya, Hirosaki, Kashiwa, Akashi, Kawasaki, Yokohama, Sendai, Hirakata
2023-12-06
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
808
Nagoya, Hirosaki, Tsukuba, Kanazawa, Sagamihara, Yokohama, Sendai, Hamamatsu
2021-04-21
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185Urinary Bladder Neoplasms
Merck Sharp & Dohme LLC
Phase 3
520
Hirosaki, Tsukuba, Takatsuki, Nagasaki, Tokyo
2020-05-19
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
1,397
Hirosaki, Tลon, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Kashihara, Hamamatsu
2018-12-24
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/city/hirosaki

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies with a site in Hirosaki that also match the filters currently applied.

How many clinical trials are recruiting in Hirosaki?

4 of the 8 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hirosaki), 8 studies
PhaseStudiesRecruitingShare
Phase 384100%

Most active sponsors

Lead sponsors with the most studies (Hirosaki)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC84
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.